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Essay

Extending Pandemic Flexibilities for Opioid Use
Disorder Treatment: Authorities and Methods
Bridget C.E. Dooling & Laura Stanley*
INTRODUCTION
In the third week of March 2020, almost two months after the
Secretary of the Department of Health and Human Services (HHS) declared COVID-19 a public health emergency,1 officers in Wyoming
County, West Virginia responded to fourteen opioid overdose calls.2
This was not unusual. From 2014 to 2016, Wyoming County had the
highest overdose death rate in West Virginia.3 One report indicates
that Wyoming County has the highest rate of prescription drug overdose deaths in the United States.4
Buprenorphine and methadone help alleviate the withdrawal
* Research Professor and Senior Policy Analyst, respectively, at the GW Regulatory
Studies Center. This Essay summarizes the findings of two reports, support for which
was provided by The Pew Charitable Trusts. Both reports are available at https://
regulatorystudies.columbian.gwu.edu/extending-pandemic-flexibilities-opioid-use
-disorder-treatment [https://perma.cc/7GWL-GRPN]. The authors thank Camille
Chambers for research assistance. Copyright © 2021 by Bridget C.E. Dooling. Copyright © 2021 by Laura Stanley.
1. U.S. DEP’T OF HEALTH & HUM. SERVS., DETERMINATION THAT A PUBLIC HEALTH
EMERGENCY
EXISTS
(2020),
https://www.phe.gov/emergency/news/
healthactions/phe/Pages/2019-nCoV.aspx [https://perma.cc/ATY7-8JWT].
2. Mary Catherine Brooks, Wyoming County Hit With 9 Overdoses in 36 Hours,
REGISTER-HERALD (Apr. 2, 2020), https://www.register-herald.com/news/crime/
wyoming-county-hit-with-9-overdoses-in-36-hours/article_cc4a34a9-b874-5da7
-8415-b1d1e941e183.html [https://perma.cc/KSB8-HGE4].
3. W. VA. DEP’T OF HEALTH & HUM. RES., 2016 WEST VIRGINIA OVERDOSE FATALITY
ANALYSIS 1, 9 (2017), https://dhhr.wv.gov/bph/Documents/ODCP%20Reports%
202017/2016%20West%20Virginia%20Overdose%20Fatality%20Analysis_
004302018.pdf [https://perma.cc/9LW8-AJZD].
4. Wendy Holdren, Report Shows Wyoming County Worst in Country for Prescription Drug Deaths, REGISTER-HERALD (Aug. 21, 2016), https://www.register
-herald.com/news/report-shows-wyoming-county-worst-in-country-for
-prescription-drug-deaths/article_123649b7-d708-5896-8cd6-040aae835ebd.html
[https://perma.cc/G8VF-3M5H].
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symptoms associated with discontinuing opioid use, reducing illicit
opioid use and resulting overdoses.5 But it is challenging for patients
in rural locations like Wyoming County to access these lifesaving medications. In Wyoming County, for example, there is only a single practitioner permitted by federal regulation to prescribe buprenorphine.6
Practitioners are required to obtain a special waiver to prescribe buprenorphine to patients with opioid use disorder, which limits the
number of available practitioners. It is even more difficult to obtain
methadone, as patients can only obtain it directly from highly regulated opioid treatment programs. The closest opioid treatment program is an hour-long drive away from the center of Wyoming County.7
Access to these treatments is highly regulated, with jurisdiction
split at the federal level between different agencies.8 It took a pandemic to break through some of the restrictions.9 To allow providers
to follow social distancing designed to limit the spread of COVID-19,
federal regulatory agencies dramatically reduced barriers to accessing buprenorphine and methadone. Although there is hope that the
COVID-19 pandemic will soon be behind us, that means the flexibilities that eased the treatment of opioid use disorder are at risk of lapsing. The opioid epidemic, on the other hand, is only getting worse.
5. See NAT’L ACADS. OF SCIS., ENG’G & MED., MEDICATION FOR OPIOID USE DISORDER
SAVES LIVES 1, 34 (2019) (noting that buprenorphine and methadone “reduce opioid
cravings and help to sever ties between opioid use and established situational or emotional triggers”).
6. Buprenorphine Practitioner Locator, SUBSTANCE ABUSE & MENTAL HEALTH SERVS.
ADMIN.,
https://www.samhsa.gov/medication-assisted-treatment/practitioner
-program-data/treatment-practitioner-locator [https://perma.cc/A27L-PUJZ].
7. Opioid Treatment Program Directory, SUBSTANCE ABUSE & MENTAL HEALTH
SERVS.
ADMIN.,
https://dpt2.samhsa.gov/treatment/directory
.aspx [https://perma.cc/7826-WLY3].
8. See Corey S. Davis & Derek H. Carr, The Law and Policy of Opioids for Pain Management, Addiction Treatment, and Overdose Reversal, 14 IND. HEALTH L. REV. 1, 15–23
(2017) (describing the complex regulatory environment for opioid addiction treatment). See generally Taleed El-Sabawi, Why the DEA, Not the FDA? Revisiting the Regulation of Potentially-Addictive Substances, 16 N.Y.U. J.L. & BUS. 317 (2020) (describing
the shift of certain responsibilities from the Food and Drug Administration to the Drug
Enforcement Agency).
9. Many others remain in place. See, e.g., Kevin Fiscella, Sarah E. Wakeman, &
Leo Beletsky, Buprenorphine Deregulation and Mainstreaming Treatment for Opioid Use
Disorder, X the X-Waiver, 76 JAMA PSYCHIATRY 229, 229–30 (2019) (describing the Xwaiver process, which requires prescribers to undergo more training to treat opioid
addiction than to prescribe opioids); Ellen M. Weber, Failure of Physicians to Prescribe
Pharmatherapies for Addiction: Regulatory Restrictions and Physician Resistance, 13 J.
HEALTH CARE L. & POL’Y 49, 55 (2010) (describing barriers that inhibit physician prescription of medication to treat addiction).
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Drug overdose deaths surged during 2020. Preliminary data suggests
more than 90,000 Americans died of drug overdoses last year.10
This Essay evaluates two specific flexibilities granted during the
COVID-19 pandemic that made it easier for patients to access buprenorphine and methadone. First, the Drug Enforcement Administration
(DEA) allowed practitioners to prescribe buprenorphine using telemedicine without first conducting an in-person medical exam. Second,
the Substance Abuse and Mental Health Services Administration
(SAMHSA) made it easier for patients to have a take-home supply of
methadone, reducing many patients’ need to make a daily trip to an
opioid treatment program. The White House Office of National Drug
Control Policy indicated that extending pandemic flexibilities for
treating opioid use disorder is a priority for the Biden Administration,
and this Essay provides a roadmap for the executive branch to do so.11
While Congress could certainly make the changes permanent
through legislation, this Essay provides an independent assessment of
whether DEA and SAMHSA have the statutory authority to extend
these flexibilities after the COVID-19 public health emergency ends by
making changes to their regulations using the notice-and-comment
rulemaking process under the Administrative Procedure Act (APA).
The main finding is that DEA and SAMHSA have regulatory mechanisms available to extend the flexibilities described above. In addition,
the U.S. HHS Secretary’s opioid-specific public health emergency declaration could offer a longer term, but still impermanent, legal pathway to extend these flexibilities beyond the current pandemic.
This Essay proceeds as follows. First, it explains the existing regulations that apply to buprenorphine induction12 using telemedicine
and the flexibilities that have been granted during the COVID-19 public health emergency. It then analyzes the authorizing statutes and
finds that DEA has the authority to extend the telemedicine flexibilities by making regulatory changes. Next, this Essay explains the
10. Paige Winfield Cunningham, The Health 202: Overdose Deaths May Have
Topped 90,000 in 2020, WASH. POST, (Apr. 7, 2021), https://www
.washingtonpost.com/politics/2021/04/07/health-202-overdose-deaths-may-havetopped-90000-2020/ [https://perma.cc/L577-BJM2].
11. OFF. OF NAT’L DRUG CONTROL POL’Y, THE BIDEN-HARRIS ADMINISTRATION’S STATEMENT
OF
DRUG POLICY PRIORITIES FOR YEAR ONE (Apr. 1, 20201),
https://www.whitehouse.gov/ondcp/briefing-room/2021/04/01/biden-harris
-administration-announces-first-year-drug-policy-priorities/
[https://perma.cc/
3F77-DYPP].
12. “Induction” is the process by which practitioners help patients begin buprenorphine treatment and set their initial dosing. Walter Ling, Larissa Mooney, & Matthew
Torrington, Buprenorphine for Opioid Addiction, 2 PAIN MGMT. 345, 347 (2012).
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existing regulations that apply to unsupervised use of methadone and
the take-home flexibilities that SAMHSA granted during the COVID-19
public health emergency. It then analyzes the authorizing statutes and
finds that SAMHSA has the authority to extend the take-home flexibilities by making regulatory changes. Lastly, it considers how DEA and
SAMHSA could use the HHS Secretary’s opioid-specific public health
emergency declaration to extend both pandemic flexibilities after the
COVID-19 public health emergency expires.
I. BUPRENORPHINE INDUCTION USING TELEMEDICINE
Buprenorphine, along with methadone, is considered a gold
standard for the treatment of opioid use disorder.13 Before the Drug
Addiction Treatment Act of 2000 (DATA 2000), practitioners could
only treat patients with buprenorphine at highly regulated opioid
treatment programs.14 DATA 2000 allowed practitioners to prescribe
buprenorphine to patients outside of opioid treatment programs, so
long as they obtain an “X” waiver from SAMHSA and DEA. To obtain an
X-waiver, a practitioner is generally required to complete a specialized eight-hour or twenty-four-hour training, submit a notification of
intent to SAMHSA, and follow certain conditions while providing buprenorphine treatment—although HHS recently exempted practitioners from the training requirement if they comply with certain conditions.15
Although SAMHSA and DEA are both responsible for regulatory
oversight of “DATA-waived practitioners,” the regulations that limit
these practitioners from using telemedicine, rooted in concerns about
diversion of controlled substances, were issued by DEA. This Part explains the DEA regulations that apply to buprenorphine induction using telemedicine, describes the flexibilities that the agency provided
to patients and practitioners during the COVID-19 public health emergency, and finds that DEA has the authority to extend the telemedicine
flexibilities through regulatory changes.
A. DEA REGULATION OF BUPRENORPHINE INDUCTION USING TELEMEDICINE
In 2009, DEA promulgated regulations implementing the Ryan
13. See id. at 346 (noting that buprenorphine “is arguably the most significant advance in the history of pharmacotherapy for opioid addiction, heralded by the introduction of methadone maintenance a half century ago”).
14. Drug Addiction Treatment Act of 2000, 21 U.S.C. § 823(g)(2) (2018).
15. Id.; Practice Guidelines for the Administration of Buprenorphine for Treating
Opioid Use Disorder, 86 Fed. Reg. 22,439 (Apr. 28, 2021).
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Haight Online Pharmacy Consumer Protection Act of 2008 (Ryan
Haight Act).16 These regulations prohibit various methods of distributing and dispensing controlled substances over the Internet, including prescribing and dispensing controlled substances without first
conducting an in-person medical evaluation.17 Since buprenorphine is
a schedule III-controlled substance, it falls under these regulations.18
The goal of the Ryan Haight Act and DEA’s implementing regulations is to halt rogue websites that allow individuals to obtain prescriptions and purchase controlled substances based on inadequate
medical evaluations.19 The primary tool the regulations use to combat
the sale of controlled substances over the Internet is the requirement
that a practitioner must give a patient at least one in-person medical
evaluation before prescribing a controlled substance. A practitioner
or facilitator who knowingly or intentionally fills a prescription for a
controlled substance without conducting an in-person medical evaluation can be held criminally liable.20
A practitioner is only permitted to prescribe controlled substances without conducting the in-person medical evaluation when
engaged in one of the rule’s seven exceptions for the “practice of telemedicine.”21 The exceptions are narrow, and patients cannot be located in their own homes to take advantage of many of them. For example, under one exception, a practitioner can initiate treatment
using telemedicine if the patient is located in and being treated by a
DEA-registered hospital or clinic.22 Alternatively, a practitioner can
initiate treatment using telemedicine if the patient is in the physical

16. DEA released an interim final rule in 2009 that was effective immediately but
did not release a final action affirming the interim final rule until 2020. See Implementation of the Ryan Haight Online Pharmacy Consumer Protection Act of 2008, 74 Fed.
Reg. 15,596 (Apr. 6, 2009); Implementation of the Ryan Haight Online Pharmacy Consumer Protection Act of 2008, 85 Fed. Reg. 61,594 (Sept. 30, 2020).
17. Congress named the Act after Ryan Haight, a young man who died of an overdose on prescription painkillers that he bought from an online pharmacy without a
valid prescription. S. REP. NO. 110-521, at 7 (2008).
18. 21 C.F.R. § 1308.13 (2019).
19. Implementation of the Ryan Haight Act, 74 Fed. Reg. 15,600–04 (Apr. 6,
2009).
20. 21 U.S.C. § 841(h)(1) of the Controlled Substances Act lays out the various
criminal liabilities for violations. A practitioner can be convicted of violating the Controlled Substances Act if they had knowledge of the illegal activity or enough information that they engaged in willful blindness. See, e.g., United States v. Katz, 445 F.3d
1023, 1031 (8th Cir. 2006).
21. 21 C.F.R. § 1300.04 (i)(1–7) (2019).
22. 21 C.F.R. § 1300.04 (i)(1) (2019).
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presence of and being treated by a DEA-registered practitioner.23
The Ryan Haight Act gives DEA the discretion to allow for telemedicine in a few other circumstances. For example, if there is a public
health emergency, such as the ongoing coronavirus public health
emergency, DEA can allow for the use of telemedicine. 24 In practice,
prior to the pandemic, patients could not be prescribed controlled
substances via telemedicine without an in-person medical examination unless they were at a DEA-registered hospital or clinic or in the
presence of a DEA-registered practitioner.
DEA argues that the Ryan Haight Act and the implementing regulations were effective in targeting rogue online pharmacies. DEA
points out that “it shut the door on the internet diversion of controlled
substances almost overnight.”25 However, as an unintended consequence it also forced legitimate telemedicine providers to first conduct in-person medical evaluations, and practitioners have pointed to
these DEA regulations as a substantial barrier to the adoption of telemedicine for treating opioid use disorder.26
The SAMHSA regulations applicable to DATA-waived practitioners are silent on whether they can initiate buprenorphine treatment
using telemedicine.27 Rather, DEA regulation of controlled substances
is the regulation that prohibits DATA-waived practitioners from initiating buprenorphine using telemedicine.
Several other regulations apply to buprenorphine induction using telemedicine. For example, prior to the public health emergency,
the Centers for Medicare & Medicaid Services (CMS) only authorized
Medicare reimbursement for telemedicine in a few circumstances,
23. The practitioner must also be acting in “the usual course of professional practice,” in accordance with state law, and be registered in the state where the patient is
located. 21 C.F.R. § 1300.04 (i)(2) (2019).
24. Specifically, the statute states when telemedicine is conducted “during a public health emergency declared by the Secretary of Health and Human Services under
section 319 of the Public Health Service Act . . . and involves patients located in such
areas, and such controlled substances, as the Secretary of Health and Human Services,
with the concurrence of the Administrator, designates,” it is considered an exempted
“practice of telemedicine.” 21 C.F.R. § 1300.04 (i)(4) (2019).
25. Loren Miller, Section Chief, Drug Enforcement Admin., Remarks at the American College of Medical Toxicology’s Mitigating the Intersection of COVID-19 and Opioid Use Disorder Panel (May 20, 2020), 45:04, https://www.youtube.com/watch?
v=t_Iu9t-AJug [https://perma.cc/FVH5-KDCA].
26. See Y. Tony Yang, Eric Weintraub, & Rebecca L. Haffajee, Telemedicine’s Role
in Addressing the Opioid Epidemic, 93 MAYO CLINIC PROC. 1177, 1178 (2018) (noting that
in-person examination requirements under the Haight Act “impede the ability of providers to prescribe buprenorphine . . . via telemedicine”).
27. 42 C.F.R. § 8 (2019).
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including brief check-ins for established patients.28 In response to the
COVID-19 public health emergency, CMS significantly relaxed reimbursement requirements for telemedicine, including for substance
use disorder treatment.29 As another example, HHS promulgated regulations under the Health Insurance Portability and Accountability
Act of 1996 (HIPAA) to protect health information involved in telemedicine, and the associated regulations require practitioners to use
video communication technology provided by certain third-party vendors.30 In response to the COVID-19 public health emergency, HHS announced it would use its enforcement discretion and not impose penalties on practitioners as long as they avoid certain technologies (e.g.,
TikTok) and operate in good faith.31 Although these regulations are
outside the scope of this Essay, they have the potential to reestablish
barriers to providing ongoing treatment using telemedicine and merit
future research.
B. DEA COVID-19 EMERGENCY FLEXIBILITIES
In response to the COVID-19 public health emergency, DEA released guidance allowing practitioners to prescribe buprenorphine to
new and existing patients with opioid use disorder over the telephone
without first requiring an in-person examination or an examination
using an audio-visual connection.32
DEA placed few limitations on practitioners’ use of the exception.
Prescriptions for buprenorphine must be issued “for a legitimate
28. Revisions to Payment Policies Under the Physician Fee Schedule and Other
Revisions to Part B for CY 2019, 83 Fed. Reg. 59,452 (Jan. 1, 2019).
29. CTRS. FOR MEDICARE & MEDICAID SERVS., MEDICARE TELEMEDICINE HEALTH CARE
PROVIDER
FACT
SHEET
(Mar.
2020),
https://www.cms.gov/newsroom/
fact-sheets/medicare-telemedicine-health-care-provider-fact-sheet [https://perma
.cc/8WEF-C5SV].
30. U.S. DEP’T OF HEALTH & HUM. SERVS., BUSINESS ASSOCIATE CONTRACTS (Jan. 25,
2013),
https://www.hhs.gov/hipaa/for-professionals/covered-entities/sample
-business-associate-agreement-provisions/index.html
[https://perma.cc/92DB
-ER9N].
31. U.S. DEP’T OF HEALTH & HUM. SERVS., NOTIFICATION OF ENFORCEMENT DISCRETION
FOR TELEHEALTH REMOTE COMMUNICATIONS DURING THE COVID-19 NATIONWIDE PUBLIC
HEALTH EMERGENCY (2020), https://www.hhs.gov/hipaa/for-professionals/special
-topics/emergency-preparedness/notification-enforcement-discretion-telehealth/
index.html [https://perma.cc/86N5-M7LW].
32. Letter from Thomas Prevoznik, Deputy Assistant Admin., Diversion Control
Div., Drug Enf’t Admin., to DEA Qualifying Practitioners (Mar. 31, 2020),
https://www.deadiversion.usdoj.gov/GDP/(DEA-DC-022)(DEA068)%20DEA%
20SAMHSA%20buprenorphine%20telemedicine%20%20(Final)%20+Esign.pdf
[https://perma.cc/48M5-6M5S].
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medical purpose by a practitioner acting in the usual course of his/her
professional practice.”33 Practitioners also must determine that an adequate evaluation can be conducted over the telephone or using an
audio-visual connection.34
DEA relies on a section of the Ryan Haight Act to provide this exception to practitioners during the pandemic. Under 21 U.S.C. §
802(54)(D), DEA has the authority to allow for the “practice of telemedicine” when it is being “conducted during a public health emergency declared by the Secretary.”35 DEA cites the COVID-19 public
health emergency declaration in its guidance.36 Accordingly, the exemption will expire when that emergency declaration expires.
C. APPROACHES TO EXTENDING FLEXIBILITIES FOR BUPRENORPHINE
INDUCTION
This Part describes two approaches DEA could take to extend the
telemedicine flexibilities granted during the COVID-19 public health
emergency post-pandemic without additional authorization from
Congress. First, DEA could issue joint regulations with SAMHSA allowing practitioners to prescribe buprenorphine without first conducting
an in-person medical evaluation. Second, DEA could establish a special
registration for telemedicine program.
1. DEA and SAMHSA Issue Joint Regulations
DEA and SAMHSA have the authority under the Ryan Haight Act
to extend the telemedicine flexibilities granted during the COVID-19
pandemic by jointly issuing regulations that allow practitioners to
prescribe buprenorphine without first conducting an in-person medical evaluation.
DEA and SAMHSA’s authority to promulgate regulations allowing
practitioners to prescribe buprenorphine using a telephone or twoway, audio-visual connection is well grounded in the law. The Ryan
Haight Act expressly gives the agencies the authority to prescribe such
regulations in 21 U.S.C. § 802(54)(G), and the history of the Ryan
Haight Act is in line with the agencies taking this action.
The language of the Ryan Haight Act unambiguously gives DEA
and SAMHSA the authority to promulgate regulations allowing for

33.
34.
35.
36.

Id.
Id.
21 U.S.C. § 802(54)(D).
Letter from Thomas Prevoznik, supra note 32.
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wider adoption of telemedicine.37 The Act says:
No controlled substance that is a prescription drug as determined under the
Federal Food, Drug, and Cosmetic Act . . . may be delivered, distributed, or
dispensed by means of the Internet without a valid prescription . . . . The term
“valid prescription” means a prescription that is issued . . . by . . . a practitioner who has conducted at least 1 in-person medical evaluation of the patient[,] or . . . a covering practitioner.38

The Act defines “covering practitioner” as “a practitioner who . . .
has conducted at least 1 in-person medical evaluation of the patient
or an evaluation of the patient through the practice of telemedicine.”39
The Act then defines seven distinct instances when a practitioner can
use telemedicine.40 These are colloquially referred to as the “seven exceptions” to the requirement to conduct an in-person exam prior to
prescribing a controlled substance using telemedicine.41
The seventh exception allows DEA and SAMHSA to issue joint regulations that permit practitioners to use telemedicine:
The term “practice of telemedicine” means, for purposes of this subchapter,
the practice of medicine in accordance with applicable Federal and State laws
by a practitioner (other than a pharmacist) who is at a location remote from
the patient and is communicating with the patient, or health care professional who is treating the patient, using a telecommunications system referred to in section 1395m(m) of title 42, which . . . is being conducted under
any other circumstances that the Attorney General and the Secretary have
jointly, by regulation, determined to be consistent with effective controls
against diversion and otherwise consistent with the public health and
safety.42

This language gives DEA and SAMHSA the discretion to promulgate regulations allowing practitioners to prescribe controlled substances using telemedicine under “any other circumstances” that the
agencies determine qualify under the Act.43 The Act also gives the
agencies discretion to ensure the regulations effectively control
against diversion and are “consistent with the public health and
safety.”44 While choices about the content of the regulations are
37. 21 U.S.C. § 802(54)(G).
38. 21 U.S.C. § 829(e)(1–2).
39. 21 U.S.C. § 829(e)(2)(C).
40. 21 U.S.C. § 802(54).
41. Thomas B. Ferrante & Sunny J. Levine, COVID-19: DEA Confirms Public Health
Emergency Exception for Telemedicine Prescribing of Controlled Substances, FOLEY INSIGHTS
(Mar.
18,
2020),
https://www.foley.com/en/insights/
publications/2020/03/covid19-public-health-exception-telemedicine
[https://
perma.cc/JKW6-H6KG].
42. 21 U.S.C. § 802(54)(G).
43. Id.
44. Id.

2021]

PANDEMIC OPIOIDS

83

generally left to the agencies, there is no ambiguity that the agencies
have the discretion to issue the regulations.
The plain language of the statute forecloses any ambiguity regarding DEA and SAMHSA’s ability to promulgate regulations that extend the telemedicine flexibilities granted during the pandemic, so
agencies and courts do not have to follow interpretive aids like legislative history.45
Although it is not authoritative, the legislative history of the Ryan
Haight Act is in tandem with the interpretation that DEA and SAMHSA
can issue regulations allowing for broader use of telemedicine.
As a Senate Judiciary Committee report explains, some Senate
leaders were concerned about hindering emerging telemedicine markets and did not intend for the Ryan Haight Act to restrict legitimate
telemedicine.46 The report points out that telemedicine can “improve
health outcomes and reduce costs” as well as offer care that is “not
available in many remote areas.”47 The Committee did not want to
place “unnecessary restrictions on the operations or growth of telemedicine,” thus, the committee report notes that:
[T]he statute provides that the Attorney General and the Secretary of Health
and Human Services may promulgate regulations that allow for the full practice of telemedicine consistent with medical practice guidelines, so long as
those regulations continue to effectively control diversion. The Committee
anticipates that the Attorney General and Secretary may update these regulations on an ongoing basis to reflect changes in telemedicine.48

Although not controlling in interpreting legislative intent, DEA
agreed that the initial medical evaluation could be conducted using
telemedicine in a 2007 hearing on the various legislative paths to regulate online pharmacies.49 When asked if Congress should require
practitioners to conduct in-person evaluations, Deputy Assistant Administrator Joseph Rannazzisi responded that “DEA believes that any
legislation that would effectively address the fraudulent prescribing
of controlled substances via the Internet must include the requirement of a legitimate medical evaluation by the prescribing practitioner, either through an in-person meeting or a valid telemedicine

45. See, e.g., Caminetti v. United States, 242 U.S. 470, 485 (1917).
46. See S. REP. NO. 110-521, at 13 (2008).
47. Id.
48. Id.
49. Rogue Online Pharmacies: The Growing Problem of Internet Drug Trafficking:
Hearing Before the S. Comm. on the Judiciary, 110th Cong. 65 (2007) (statement of Joseph Rannazzisi, Deputy Assistant Administrator, Drug Enforcement Administration).
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consultation meeting appropriate criteria.”50 Thus, during the development of the Ryan Haight Act, DEA signaled to legislators that, in its
view, the initial evaluation could be conducted via telemedicine.
a. Potential Legal Barriers to Extending the Pandemic Flexibilities
Through Joint Regulations
Although DEA and SAMHSA have the legal authority to issue joint
regulations, there are two potential legal barriers to address should
the agencies issue regulations replicating the pandemic-related flexibilities. First, the Ryan Haight Act requires providers to use a “telecommunications system.” The definition of that term determines the
type of telemedicine (e.g., audio-visual only) that DEA and SAMHSA
could authorize. Second, this approach raises the question of whether
DEA and SAMHSA have discretion to issue joint regulations without
incorporating additional diversion controls. This section concludes
that neither is a legal barrier that should interfere with this approach.51
i.

The Requirement to Use a “Telecommunications System”

The Ryan Haight Act, which established the seven telemedicine
exceptions, also includes a relevant limitation to those exceptions.52
The statute requires that the “practice of telemedicine” be conducted
“using a telecommunications system referred to” in the Medicare,
Medicaid, and SCHIP Benefits Improvement and Protection Act of 200l
(BIPA).53
Both DEA and SAMHSA pandemic flexibilities allow practitioners
prescribing buprenorphine to do so over the telephone (i.e., using only
50. Id. at 14.
51. This Essay does not go into significant depth on two other statutes applicable
to DATA-waived practitioners and opioid treatment programs because they are not
legal barriers. First, DATA 2000 amended the Controlled Substances Act to provide a
process for practitioners to get a waiver to prescribe buprenorphine without registering with DEA as an opioid treatment program, but the statute is silent on prescribing
buprenorphine using telemedicine. Drug Addiction Treatment Act of 2000, 21 U.S.C. §
823(g)(2) (2018). Second, the Narcotic Addict Treatment Act of 1974 amended the
Controlled Substances Act to require practitioners dispensing controlled substances
for maintenance or detoxification treatment to obtain a separate registration with DEA
and comply with standards developed by HHS for opioid treatment programs, but the
statute is also silent on prescribing controlled substances using telemedicine. Narcotic
Addict Treatment Act of 1974, 21 U.S.C. § 823(g)(2) (2018).
52. 21 U.S.C. § 802(54).
53. Medicare, Medicaid, and SCHIP Benefits Improvement and Protection Act of
200l, 42 U.S.C. § 1395m(m); 21 U.S.C. § 802(54).
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an audio connection). The agencies did not limit practitioners to use
of a two-way, audio-visual connection.54 The agencies also permit telephone consultations to suffice, which is important from a policy perspective because many low-income, homeless, or recently incarcerated patients do not have reliable access to computers or smartphones
with video cameras.55 Thus, when considering whether a Ryan Haight
Act exception could be the basis for additional telemedicine flexibility,
this raises the question of whether a telephone qualifies as a “telecommunications system.”
As mentioned, the “practice of telemedicine” must be conducted
“using a telecommunications system referred to” in the Medicare,
Medicaid, and SCHIP Benefits Improvement and Protection Act of 200l
(BIPA).56 BIPA, however, does not define “telecommunications system.” The relevant provision simply states that HHS will pay for “telehealth services furnished via a telecommunications system by a physician.”57 Although BIPA does not define “telecommunications
systems,” the CMS promulgated a regulatory definition to be used in
its programs. In the preamble to the proposed rule implementing
BIPA, CMS confirmed that Congress did not define “telecommunications system.” 58 In response, CMS promulgated a definition of “telecommunications system” that excludes telephones.59 While the CMS
definition shows one approach to interpreting the term “telecommunications system,” CMS did not purport to bind DEA or SAMHSA to its
definition.
The plain language of the statute suggests that DEA and SAMHSA
may interpret “telecommunications system” broadly to include an audio-only connection. The dictionary definition of the word “telecommunication” expressly includes “communication at a distance (as by
54. Letter from Thomas Prevoznik, supra note 32; SUBSTANCE ABUSE & MENTAL
HEALTH SERVS. ADMIN., FAQS: PROVISION OF METHADONE AND BUPRENORPHINE FOR THE
TREATMENT OF OPIOID USE DISORDER IN THE COVID-19 EMERGENCY (Apr. 21, 2020),
https://www.samhsa.gov/sites/default/files/faqs-for-oud-prescribing-and
-dispensing.pdf [https://perma.cc/G87S-N9XG] [hereinafter SAMHSA FAQS].
55. Jocelyn Guyer & Karen Scott, State Strategies for Helping Individuals with Opioid Use Disorder Through the COVID-19 Epidemic, HEALTH AFFS. BLOG (May 2, 2020),
https://www.healthaffairs.org/do/10.1377/hblog20200429.476954/full/ [https://
perma.cc/QEK4-8RDV].
56. Medicare, Medicaid, and SCHIP Benefits Improvement and Protection Act of
200l, 42 U.S.C. § 1395m(m) (2018); 21 U.S.C. § 802(54).
57. 42 U.S.C. § 1395m(m)(1).
58. Medicare Programs; Revisions to Payment Policies Under the Physician Fee
Schedule for Calendar Year 2002, 66 Fed. Reg. 40,372 40,393 (Aug. 2, 2001).
59. 42 CFR § 410.78(a)(3) (2019).
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telephone).”60
More directly relevant, and as discussed above, both DEA and
SAMHSA pandemic flexibilities allow practitioners prescribing buprenorphine to do so over the telephone (i.e., using only an audio connection).61 Importantly, in taking this posture, DEA and SAMHSA signaled that they read “telecommunications system” expansively to
include telephone communications for purposes of their own programs. Therefore, as applied to DEA and SAMHSA, the definition of
“telecommunications system” does not appear to be a legal barrier to
DEA-SAMHSA joint regulations under 21 U.S.C. § 802(54)(G).
ii. Incorporating Additional Diversion Controls
The Ryan Haight Act limits the practice of telemedicine pursuant
to DEA-SAMHSA joint regulations to circumstances “determined [by
the agencies] to be consistent with effective controls against diversion
and otherwise consistent with the public health and safety.”62 That
language raises the question of whether DEA and SAMHSA need to incorporate additional diversion controls if they issue joint regulations,
or if the diversion controls included in the pandemic-related flexibilities are sufficient to satisfy the statute.
Although Congress has spoken to the issue, the statutory language is ambiguous because it does not articulate what constitutes an
effective control.63 The legislative history of the Ryan Haight Act is silent as to the types of diversion control requirements the agencies
ought to place on practitioners using telemedicine.64
Given that Congress deferred to the agencies’ discretion on this
matter, it is instructive to consider their pandemic approach. The
agencies’ pandemic-related flexibilities suggests that DEA and SAMHSA were not concerned enough about the potential for diversion to
place additional controls on practitioners.65 To take advantage of the
pandemic-related flexibilities, a practitioner must ensure that he or
she can conduct an adequate evaluation using telemedicine, which includes the use of telephone.66 The current regulations already require
60. Telecommunication, MERRIAM-WEBSTER, https://www.merriam-webster
.com/dictionary/telecommunication [https://perma.cc/F8NS-HLGW].
61. Letter from Thomas Prevoznik, supra note 32; SAMHSA FAQS, supra note 54.
62. 21 U.S.C. § 802(54)(G).
63. 21 U.S.C. § 802(54).
64. Id.; see supra Part I.C.1 for more discussion on the legislative history.
65. Letter from Thomas Prevoznik, supra note 32; SAMHSA FAQS, supra note 54.
66. The exception does not apply to new opioid treatment program patients
treated with methadone. Letter from Thomas Prevoznik, supra note 32; SAMHSA FAQS,
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an evaluation—the pandemic-related flexibilities simply allow evaluation to be conducted over the telephone or using an audio-visual connection. The flexibilities require the telemedicine practitioner to be
state-licensed and DEA-registered, which is also consistent with current regulations.67 Additionally, and consistent with current regulations, prescriptions for buprenorphine must be issued “for a legitimate medical purpose by a practitioner acting in the usual course of
his/her professional practice.”68
Of course, when DEA and SAMHSA crafted these regulatory flexibilities, they did so prospectively. Careful research could help inform
the impact these flexibilities are having on controlled substance diversion. Research could further reveal whether DEA and SAMHSA should
issue regulations similar to the flexibilities granted during the pandemic public health emergency or should change course. In the meantime, and absent any evidence of increased diversion, it is reasonable
to conclude that it is within DEA and SAMHSA’s discretion to issue
joint regulations without imposing additional diversion controls.69
2. DEA Establishes a Special Registration for Telemedicine Program
As a second potential path to extend the telemedicine pandemic
flexibilities, DEA can use its authority to establish a special registration for telemedicine programs. One of the seven telemedicine exceptions in the Ryan Haight Act gives DEA the discretion to register practitioners to prescribe controlled substances using telemedicine.70 The
statute says, “the term ‘practice of telemedicine’ means, for purposes
of this subchapter, the practice of medicine . . . which . . . is being conducted by a practitioner who has obtained from the Attorney General
supra note 54.
67. Letter from Thomas Prevoznik, supra note 32.
68. Id.
69. While the exact content and process of these rules are outside the scope of
this Essay, the agencies would need to promulgate these rules consistent with the Administrative Procedure Act and in such a manner as to survive judicial review under
the Chevron doctrine. Chevron U.S.A. Inc. v. NRDC Inc., 467 U.S. 837 (1984). In this Essay, we focus on the agencies’ statutory authorities to take these actions, which is only
one of the issues that could come up in subsequent litigation.
70. DEA planned to create a special registration program in 2009 when it first
released rules implementing the Ryan Haight Act. Implementation of the Ryan Haight
Online Pharmacy Consumer Protection Act of 2008, 74 Fed. Reg. 15,596 (Apr. 6, 2009).
In the Special Registration for Telemedicine Act of 2018, Congress directed DEA to finalize a special registration program to increase access to telemedicine for substance
use disorder by October 24, 2019. DEA missed the deadline and has yet to release proposed regulations. Special Registration for Telemedicine Act of 2018, 21 U.S.C. §
831(h)(2).
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a special registration.”71 Therefore, DEA’s legal authority to create
such a program is clear.
In fact, recent legislation requires DEA to create a special registration program. The Special Registration for Telemedicine Act of
2018, part of the SUPPORT for Patients and Communities Act, gave
DEA until October 2019 to release final regulations “specifying . . . the
limited circumstances in which a special registration . . . may be issued
to a practitioner to engage in the practice of telemedicine.”72 Although
DEA missed the initial deadline, it remains legally obligated to create
this special registration program.73
Whether a special registration promotes the use of telemedicine
depends on how it is designed. DEA’s special registration for telemedicine program could open up a new pathway for the practice of telemedicine compared to current regulations. The special registration
could also be so burdensome for practitioners that it has no significant
effect on telemedicine uptake. If DEA designs a program that requires
a practitioner to undergo extensive training and then apply and wait
for DEA to grant the registration, such a special registration is unlikely
to lead to increased uptake.
DEA has the authority to pursue a creative approach when activating the special registration program. The statute gives DEA the discretion to “specif[y] . . . the limited circumstances in which a special
registration” may be issued.74 The statute does not require DEA to preapprove each individual practitioner seeking a special registration for
telemedicine.75 DEA could automatically issue a special registration to
each practitioner who applies for a regular DEA registration or renews his or her registration, for example. Alternatively, DEA could require practitioners to submit a separate application for a special registration program. With either method, DEA could impose the same
requirements on practitioners using a special registration for telemedicine as it did on practitioners utilizing the telemedicine flexibility
during the COVID-19 pandemic.76
71. 21 U.S.C. § 802(54)(E).
72. 21 U.S.C. § 831(h)(2).
73. Malka Berro, DEA Misses Deadline for Teleprescribing Special Registration,
NAT’L COUNCIL FOR BEHAVIORAL HEALTH (Oct. 31, 2019), https://www
.thenationalcouncil.org/capitol-connector/2019/10/dea-misses-deadline-for
-teleprescribing-special-registration/ [https://perma.cc/QG8M-RJKN].
74. 21 U.S.C. § 831(h)(2).
75. Id.
76. It is permissible for DEA to both release a special registration program and
promulgate joint regulations with SAMHSA. Although this approach would require
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II. UNSUPERVISED USE OF METHADONE
Over 400,000 people in the United States receive methadone
from an opioid treatment program to treat their opioid use disorders.77 Methadone is significantly more effective at reducing opioid
use and retaining patients in treatment than approaches that do not
use medication.78 For many people, taking methadone to treat opioid
use disorders involves a daily trip to the opioid treatment facility to
receive medication administered at the facility.79
Although taking a daily trip to an opioid treatment program was
already a logistical challenge for patients, the COVID-19 pandemic
heightened obstacles for patients who need to travel every day to receive their medication. Practitioners reported that many opioid treatment programs reduced their hours, and some stopped accepting new
patients altogether.80 There are also reports of crowded waiting
rooms and long lines of people not socially distanced.81
Even before the pandemic, access to opioid treatment programs
was limited. Over 90 percent of opioid treatment programs are located in urban areas, making it challenging for rural patients to make
the daily trip to receive their medication.82 Studies have established
that longer travel distance reduces the likelihood that people with
substance use disorder complete treatment or seek aftercare.83 One
DEA to write two separate regulations and go through the notice-and-comment process twice, it might save the agency administrative resources in the long run.
77. SUBSTANCE ABUSE & MENTAL HEALTH SERVICES ADMIN., NATIONAL SURVEY OF SUBSTANCE ABUSE TREATMENT SERVICES (N-SSATS): 2019, at 113 (July 2020),
https://www.samhsa.gov/data/sites/default/files/reports/rpt29389/NSSATS
-2019.pdf [https://perma.cc/5FDH-Y5L8].
78. Richard P. Mattick, Courtney Breen, Jo Kimber, & Marina Davoli, Methadone
Maintenance Therapy Verses No Opioid Replacement Therapy for Opioid Dependence, 3
COCHRANE LIBR. 1, 2 (2009).
79. See, e.g., Jennifer D. Oliva, Policing Opioid Use Disorder in a Pandemic, U. CHI. L.
REV.
ONLINE
(NOV.
16,
2020),
https://lawreviewblog
.uchicago.edu/2020/11/16/covid-oliva/ [https://perma.cc/LCA2-S8DG].
80. Kate Briquelet, Don’t Forget the Other Pandemic Killing Thousands of Americans, DAILY BEAST (May 4, 2020), https://www.thedailybeast.com/opioid-deaths
-surge-during-coronavirus-in-americas-overdose-capitals (last visited Oct. 25, 2021).
81. Alison Insinger, Methadone Clinic Lines and Packed Waiting Rooms Leave Clients Vulnerable to the Coronavirus, STAT NEWS (Apr. 9, 2020), https://www
.statnews.com/2020/04/09/methadone-clinics-leave-clients-vulnerable-to
-coronavirus/ [https://perma.cc/Q53W-62PY].
82. Registration Requirements for Narcotic Treatment Programs with Mobile
Components, 85 Fed. Reg. 11,008 (Feb. 26, 2020).
83. Kyle Beardsley, Eric D. Wish, Dawn Bonanno Fitzelle, Kevin O’Grady, & Amelia
M. Arria, Distance Traveled to Outpatient Drug Treatment and Client Retention, 25 J.
SUBSTANCE ABUSE TREATMENT 279, 279 (2003); Susan K. Schmitt, Ciaran S. Phibbs, &
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study found that patients traveling more than a mile to treatment programs were roughly fifty percent less likely to complete treatment
than patients who traveled less than a mile.84
Allowing patients to take home extra doses of methadone from
an opioid treatment program is an effective way to ensure that patients have access to methadone, but SAMHSA has traditionally placed
significant limits on allowing patients to have take-home doses. This
Part explains the SAMHSA regulations that apply to the unsupervised
use of methadone, describes the flexibilities that agency provided to
patients and practitioners during the COVID-19 public health emergency, and finds that SAMHSA has the authority to extend the unsupervised use flexibilities through regulatory changes.
A. REGULATIONS FOR TAKE-HOME SUPPLIES OF OPIOID TREATMENT
MEDICATION
Under the Narcotic Addict Treatment Act of 1974, SAMHSA is responsible for regulatory oversight of “opioid treatment programs,”
which SAMHSA defines as inclusive of any practitioner or program
that is registered with DEA and treats a patient with a drug that is approved by the Food and Drug Administration (FDA) for treatment of
opioid use disorder.85 This definition includes practitioners and programs that use buprenorphine or methadone as part of a protocol to
treat opioid use disorder. As of 2018, there were 1,605 opioid treatment programs in the United States.86 When used to treat opioid use
disorder, methadone can only be dispensed at an opioid treatment
program.87
SAMHSA’s requirements for opioid treatment programs are extensive. For example, opioid treatment programs must provide counseling services to patients, document patient care and outcomes, and
limit the amount of a medication a patient can take home.88
John D. Piette, The Influence of Distance on Utilization of Outpatient Mental Health Aftercare Following Inpatient Substance Abuse Treatment, 28 ADDICTIVE BEHAVIORS 1183,
1183 (2003).
84. Beardsley et al., supra note 83, at 283.
85. Narcotic Addict Treatment Act of 1974, 21 U.S.C. § 823(g)(2) (2018); 42 C.F.R.
§ 8.2 (2019).
86. Christopher M. Jones, Danielle J. Byrd, Thomas J Clarke, Tony B. Campbell,
Chideha Ohuoha & Elinore F. McCance-Katz, Characteristics and Current Clinical Practices of Opioid Treatment Programs in the United States, 205 DRUG & ALCOHOL DEPENDENCE 1, 2 (2019).
87. 42 C.F.R. § 8 (2019); 21 C.F.R. § 1306.04(c) (2019).
88. 42 C.F.R. § 8 (2019).
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The requirements for the take-home supply, or unsupervised use,
of methadone are particularly extensive. Practitioners must take into
consideration eight criteria when determining if a patient is “responsible” enough to have a take-home supply of medication:
In determining which patients may be permitted unsupervised use, the medical director shall consider the following take-home criteria in determining
whether a patient is responsible in handling opioid drugs for unsupervised
use.
(i) Absence of recent abuse of drugs (opioid or nonnarcotic), including
alcohol;
(ii) Regularity of clinic attendance;
(iii) Absence of serious behavioral problems at the clinic;
(iv) Absence of known recent criminal activity, e.g., drug dealing;
(v) Stability of the patient’s home environment and social relationships;
(vi) Length of time in comprehensive maintenance treatment;
(vii) Assurance that take-home medication can be safely stored within the
patient’s home; and
(viii) Whether the rehabilitative benefit the patient derived from decreasing
the frequency of clinic attendance outweighs the potential risk of diversion.89

If a practitioner determines that a patient is sufficiently responsible under these eight criteria to be eligible to receive a take-home
supply of methadone, the number of doses is initially limited and gradually increases. For example, during the first ninety days of treatment,
patients can only take home one dose per week of methadone.90 This
means patients must still go to the opioid treatment program the
other six days of the week for their daily dose of methadone.91 In the
second ninety days of treatment, a patient can take home two doses
per week.92 The number increases with the time-in-treatment; after a
year of continuous treatment, a patient can take home a two-week
supply.93 After two years of continuous treatment, the flexibility
maxes out and a patient can begin to take home a one-month supply.94
The rationale originally put forward to support the time-in-treatment requirement was that “the longer the patient is in treatment[,]
the greater the likelihood he or she has of establishing a therapeutic
relationship with the counselor and the program and the greater
89. 42 C.F.R. § 8.12(i)(2).
90. 42 C.F.R. § 8.12(i)(3)(i).
91. A patient might only need to go for five other days if the opioid treatment
program closes for a day on Sunday or for State or Federal holidays. 42 CFR §
8.12(i)(1).
92. 42 C.F.R § 8.12(i)(3)(ii).
93. 42 C.F.R § 8.12(i)(3)(v).
94. 42 C.F.R § 8.12(i)(3)(vi).
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likelihood he or she has of being assessed properly against the [eight
criteria].”95 The agency, which was the FDA at the time, did not offer
evidence to support the idea that the time-in-treatment requirement
encourages patients to stay in treatment longer. When SAMHSA took
over this regulatory program, it maintained this eight-criteria test.96
DEA regulations do not impose specific requirements regarding
the unsupervised use of methadone or buprenorphine. Rather, the
agency defers to SAMHSA regulations regarding unsupervised use.97
Although DEA regulations apply multiple restrictions to narcotic
treatment programs, those restrictions do not appear to bear on takehome supplies.98
B. COVID-19-RELATED FLEXIBILITIES
In response to the COVID-19 public health emergency, SAMHSA
released a guidance document that allows state regulatory authorities
to request blanket exceptions to allow patients to take home more
doses of methadone and buprenorphine.99 The guidance says that for
all states,
[t]he state may request blanket exceptions for all stable patients in an OTP to
receive 28 days of Take-Home doses of the patient’s medication for opioid
use disorder. The state may request up to 14 days of Take-Home medication
for those patients who are less stable but who the OTP believes can safely

95. Drugs Used for Treatment of Narcotic Addicts; Joint Revision of Conditions for
Use, 45 Fed. Reg. 62,692, 62,704 (Sept. 19, 1980).
96. Narcotic Drugs in Maintenance and Detoxification Treatment of Narcotic Dependence, 64 Fed. Reg. 39,810, 39,822 (proposed July 22, 1999); Opioid Drugs in
Maintenance and Detoxification Treatment of Opiate Addiction, 66 Fed. Reg. 4,076,
4,098 (Jan. 17, 2001). This test looks especially overdue for policy review. A number
of the criteria appear so subjective as to amplify problematic biases where they exist.
The extent to which these criteria serve as a barrier to treatment is beyond the scope
of this Essay but would benefit from additional study.
97. 21 C.F.R. § 1301.74(k) (2019). The DEA regulations refer to SAMHSA regulations and state that “[a]ll narcotic treatment programs must comply with standards
established by the Secretary of Health and Human Services (after consultation with the
Administration) respecting the quantities of narcotic drugs which may be provided to
persons enrolled in a narcotic treatment program for unsupervised use.” Id.
98. DEA’s security controls for narcotic treatment programs, for example, require
such programs to keep controlled substances in a safe or steel cabinet and to notify
DEA of theft and significant loss of methadone. 21 C.F.R. § 1301.72(a–b) (2019); 21
C.F.R. § 1301.74(c) (2019).
99. SUBSTANCE ABUSE & MENTAL HEALTH SERVS. ADMIN., OPIOID TREATMENT PROGRAM
(OTP) GUIDANCE (Mar. 19, 2020), https://www.samhsa.gov/sites/default/files/
otp-guidance-20200316.pdf [https://perma.cc/QBQ8-MQ32] [hereinafter SAMHSA
OTP GUIDANCE].
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handle this level of Take-Home medication.100

The guidance document and the regulations at 42 CFR § 8.12 do
not define “stable patient” or “less stable patient,” nor do they include
any description about who qualifies as “stable.” Thus, SAMHSA’s guidance is unclear about whether opioid treatment programs should use
the eight take-home criteria laid out in 42 CFR § 8.12(i)(2) or different
criteria. Some practitioners interpreted the pandemic-related guidance to mean that SAMHSA is deferring to the opioid treatment programs to decide when a patient is “stable” or “less stable.”101 Others
interpreted it differently to mean the eight take-home criteria should
be used to determine if a patient is “stable” or “less stable.”102
In its guidance, SAMHSA did not place any specific requirements
on practitioners who want to take advantage of this flexibility once
their state adopts the blanket exemption. SAMHSA neither mentions
the statute or regulation that authorizes it to provide this flexibility to
opioid treatment programs, nor specifies whether the flexibility is set
to expire when the COVID-19 emergency declaration expires or is revoked.103
Some states, such as Massachusetts and New Jersey, requested
the exemption to permit some patients in their states to receive the
larger take-home supply of fourteen to twenty-eight days of medication.104 Some localities allowed for smaller increases in take-home
supplies. New York City, for example, allowed patients to start with a
two or three-day take-home supply.105
C. APPROACHES TO EXTENDING FLEXIBILITIES FOR THE UNSUPERVISED USE
OF OPIOID TREATMENT MEDICATIONS
This Part finds that SAMHSA has the legal authority to extend the
flexibilities granted during the COVID-19 public health emergency
without additional authorization from Congress. It describes two
100. Id.
101. Insinger, supra note 81.
102. Helen Redmond, SAMHSA’s Absurd Criteria for Identifying “Stable” Methadone
Patients, FILTER (Mar. 31, 2020), https://filtermag.org/samhsa-methadone-criteria/
[https://perma.cc/QAJ6-7WAA].
103. This differs from guidance issued by DEA in response to the COVID-19 public
health emergency declaration that allows DATA-waived practitioners to prescribe buprenorphine to new and existing patients over the telephone without first requiring
an in-person examination. In that guidance, DEA wrote that it provided the flexibility
due to the COVID-19 public health emergency, and it is set to expire when the emergency declaration expires or is revoked. Letter from Thomas Prevoznik, supra note 32.
104. Guyer & Scott, supra note 55.
105. Insinger, supra note 81.
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approaches that the agency could take. First, SAMHSA could use its
statutory authority to issue a rule codifying the flexibilities after consulting with DEA. Second, SAMHSA could release a new guidance document implementing these changes.
1. SAMHSA Issues Regulations After Consultation with DEA
SAMHSA has the authority under the Narcotic Addict Treatment
Act to extend the pandemic-related flexibilities by issuing regulations
through the notice-and-comment rulemaking process.106 The only
condition the statute places on SAMHSA is the requirement that the
agency consult with DEA before issuing the regulations.107
The language of the Act unambiguously gives SAMHSA this authority. The Act says:
The Attorney General shall register a [practitioner] to dispense narcotic
drugs to individuals for maintenance treatment or detoxification treatment
(or both) (A) if the applicant is a practitioner who is determined by the Secretary to be qualified (under standards established by the Secretary) to engage in the treatment with respect to which registration is sought . . . and (C)
if the Secretary determines that the applicant will comply with standards established by the Secretary (after consultation with the Attorney General) respecting the quantities of narcotic drugs which may be provided for unsupervised use by individuals in such treatment.108

This language plainly gives SAMHSA broad authority to establish
the standards that practitioners must follow to dispense narcotic
drugs to individuals for maintenance or detoxification treatment (i.e.,
the standards that opioid treatment programs must follow).
It also gives SAMHSA broad authority to set standards regarding
the quantity of methadone or buprenorphine an opioid treatment program can give a patient to take home, and it does not limit the circumstances for which SAMHSA can authorize unsupervised use. SAMHSA
has the authority, for example, to extend the pandemic-related flexibilities by promulgating a regulation allowing states to request blanket exemptions for all stable patients to receive twenty-eight days of
take-home medication and less stable patients to receive fourteen
days of take-home medication after consultation with DEA.
In fact, SAMHSA has the authority to provide flexibilities that extend beyond the pandemic-related flexibilities. For example, SAMHSA
could modify its regulations at 42 CFR § 8.12(i)(3) to remove or modify the time-in-treatment requirement for all patients who have been
106. Narcotic Addict Treatment Act of 1974, 21 U.S.C. § 823(g)(1) (2018).
107. Id.
108. Id.
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deemed stable enough to have a take-home supply. Alternatively, the
regulations could permit any patient who an opioid treatment program deems “stable” to have access to fourteen or twenty-eight days
of take-home supply. SAMHSA could remove the eight take-home criteria from the regulations and defer to the opioid treatment program
to make the decision about when a patient is “stable.” If SAMHSA
amended the regulations in this manner, states would not need to request an exemption from SAMHSA, and states that incorporate SAMHSA’s regulations by reference would not need to take any additional
action to allow for such in-state flexibility.109 This is one of many approaches SAMHSA could take to modify its regulations for unsupervised use.
To support regulatory changes like this, SAMHSA would need to
build an administrative record to support the changes. This is one area
where on-the-ground experience with the current regulations and
pandemic flexibilities could help support SAMHSA’s rationale for a
regulatory change.110 The statute also requires SAMHSA to consult
with DEA prior to issuing such regulations, so the agency would need
to communicate with DEA and include a description of the consultation in the rulemaking record before issuing the rule.111
SAMHSA explained that the restrictions on unsupervised use “are
intended to reduce the risk of abuse and diversion of opioid treatment
109. New Jersey’s regulations, for example, stipulate that opioid treatment programs only need to request an exemption from the take-home requirements if the
“treatment decision . . . differs from the Federal regulatory requirements at 42 CFR
Part 8.” N.J. ADMIN. CODE §10:161B-11.1 (2020). Thus, New Jersey would not need to
modify its administrative code to allow for expanded take-home use. Alternatively,
Massachusetts promulgates regulations that are more stringent than the federal regulations for take-home use. For example, during the first two months of treatment, patients can have no take-home doses. 105 MASS. CODE REGS. § 164.000 (2016). Massachusetts would need to amend it regulations to allow for expanded take-home use.
These scenarios, where state action is needed to implement SAMHSA’s regulatory
changes, create an additional barrier to extending the pandemic-related flexibilities.
Although state-level barriers are outside the scope of this Essay, they warrant further
scrutiny.
110. Research is already beginning to be published. See, e.g., Sarah Brothers, Adam
Viera, & Robert Heimer, Changes in Methadone Program Practices and Fatal Methadone
Overdose Rates in Connecticut During COVID-19, 131 J. SUBSTANCE ABUSE TREATMENT 1,
4 (2021) (“We see no evidence that increased take-home doses led to increased methadone-related fatal overdoses.”); Mary C. Figgatt, Zach Salazar, Elizabeth Day, Louise
Vincent, & Nabarun Dasgupta, Take-Home Dosing Experiences Among Persons Receiving
Methadone Maintenance Treatment During COVID-19, 123 J. SUBSTANCE ABUSE TREATMENT 1, 1 (2021) (finding minimal amounts of reported diversion among participants
receiving take-home doses under the COVID-19 flexibility).
111. 21 U.S.C. § 823(g)(1).
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medication that have abuse potential.”112 However, recent research
suggests that there has been minimal diversion associated with unsupervised use during the COVID-19 public health emergency.113 A study
anonymously surveyed eighty-seven patients receiving methadone
take-home doses since SAMHSA issued the pandemic-related flexibility doses and found minimal reported levels of diversion of the takehome doses.114
2. SAMHSA Issues a New Guidance Document
As noted above, in response to the COVID-19 public health emergency, SAMHSA released a guidance document that allows state regulatory authorities to request blanket exceptions to allow patients to
take home additional doses of methadone and buprenorphine.115 This
guidance document does not reference the COVID-19 public health
emergency declaration. It also does not discuss SAMHSA’s legal authority to provide this flexibility. However, SAMHSA’s clearest authority to extend these flexibilities through guidance comes from 42 C.F.R.
§ 8.11(h).
SAMHSA has the regulatory authority at 42 C.F.R. § 8.11(h) to
grant opioid treatment programs exemptions from various requirements.116 This regulation states that “[a]n [opioid treatment program]
may, at the time of application for certification or any time thereafter,
request from SAMHSA exemption from the regulatory requirements
set forth under this section and § 8.12 . . . SAMHSA will approve or
deny such exemptions at the time of application, or any time thereafter, if appropriate.”117 Opioid treatment programs seeking an exemption must provide rationale for the exemption with thorough documentation, and SAMHSA can approve or deny the exemption after
consulting with the state regulatory authority.118
Although this regulatory authority clearly grants SAMHSA the
ability to consider exemption requests from opioid treatment programs on a case-by-case basis, SAMHSA also used this regulatory authority to grant broad relief in other guidance related to the COVID-19
public health emergency. For example, SAMHSA released a guidance
112. Opioid Drugs in Maintenance and Detoxification Treatment of Opiate Addiction, 77 Fed. Reg. 72,752, 72,753 (Dec. 6, 2012).
113. Figgatt et al., supra note 110.
114. Id.
115. SAMHSA OTP GUIDANCE, supra note 99.
116. 42 CFR § 8.11(h) (2019).
117. Id.
118. Id.
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document that exempts opioid treatment programs from the requirement to conduct an in-person evaluation before admitting a new patient to the program for buprenorphine treatment.119 In that guidance
document, SAMHSA points to its regulatory authority at 42 C.F.R. §
8.11(h), as opposed to its authorizing statute or the public health
emergency declaration, for the legal authority to grant the exception.
Thus, SAMHSA is not bound by the presence of a public health
emergency to draw again on this regulatory authority to grant a broad
exception expanding unsupervised use. Based on its prior assessment
of its authority in 42 C.F.R. § 8.11(h), SAMHSA can release a guidance
document that, for example, allows states to request blanket exemptions for all stable patients to receive twenty-eight days of take-home
medication and less stable patients to receive fourteen days of takehome medication after consultation. This approach could be especially helpful if the guidance clarifies that opioid treatment programs
have discretion to determine what “stable” means and are not required to use the eight take-home criteria to determine when a patient
can have a take-home supply. SAMHSA could pair this approach with
an effort to evaluate its effects to inform future decision making.
III. A SEQUENCED APPROACH TO EXTENDING THE FLEXIBILITIES
The suggested pathways above give SAMHSA and DEA options to
extend the pandemic flexibilities on an ongoing basis. If the agencies
pursue rulemaking, they will need time to complete it, perhaps longer
than the duration of the rest of this pandemic. In the meantime, the
agencies could pivot to the opioid-specific public health emergency to
justify extensions of these flexibilities. The Secretary of HHS can declare a public health emergency under the Public Health Service
Act.120 A public health emergency determination triggers emergency
powers that permit the federal government to engage in special activities like spending funds on the emergency or suspending or modifying regulatory requirements.121 On October 26, 2017, Acting Secretary
of HHS Eric Hargan declared the opioid crisis a nationwide public
health emergency.122 The opioid crisis public health emergency has
since been renewed fourteen times; most recently by HHS Secretary
119. SAMHSA FAQS, supra note 54. Although buprenorphine is more leniently regulated and can be prescribed by DATA-waived practitioners, it is occasionally dispensed directly to patients at opioid treatment programs.
120. Public Health Service Act of 1944, 42 U.S.C. § 247d.
121. Id.
122. U.S. DEP’T OF HEALTH & HUM. SERVS., supra note 1.
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Xavier Becerra on April 7, 2021.123 To the extent that this public health
emergency declaration continues to be extended, it could be used to
support the extension of the pandemic flexibilities long enough to give
the agencies time to complete rulemaking.
Turning to the DEA flexibilities first, DEA relied on the COVID-19
public health emergency as the basis for its action to permit telemedicine. As discussed above, under 21 U.S.C. § 802(54)(D), DEA has the
authority to allow the “practice of telemedicine” when it is being “conducted during a public health emergency declared by the Secretary
under section 247d of title 42.”124 Both the opioid crisis and the
COVID-19 public health emergencies were declared under section
247d. Just as DEA used its authority to allow for the initial evaluation
to be conducted via telemedicine during the COVID-19 public health
emergency, it has the discretion as a matter of law to use that authority to extend that policy under the opioid-specific public health emergency.
Second, just as SAMHSA used its regulatory authority at 42 C.F.R.
§ 8.11(h) to exempt opioid treatment programs from the requirement
to conduct an in-person evaluation to admit a new patient for the purposes of buprenorphine treatment during the COVID-19 public health
emergency, it can use that regulatory authority to extend this exemption under the opioid-specific public health emergency. It can also use
that regulatory authority to allow for increased unsupervised use, but
it could choose to make this exemption contingent on the continuation
of the opioid-specific public health emergency. As explained above,
the regulatory authority at 42 C.F.R. § 8.11(h) does not require a public health emergency declaration for SAMSHA to provide exemptions
to the regulations in § 8.12.125 That provision gives the agency the discretion to exempt opioid treatment programs from any regulations in
§ 8.12 and does not stipulate the circumstances in which SAMHSA can
provide the exemption.126
This option would not provide a permanent solution standing on
its own, since the flexibilities would expire if or when the opioid123. U.S. DEP’T OF HEALTH & HUM. SERVS., RENEWAL OF DETERMINATION THAT A PUBLIC
HEALTH EMERGENCY EXISTS (2021), https://www.phe.gov/emergency/news/
healthactions/phe/Pages/opioids-7April2021.aspx [https://perma.cc/3EV4-TRLF]. A
public health emergency determination remains in effect for ninety days or until the
Secretary determines the emergency no longer exits, meaning the Secretary must renew an emergency in ninety-day increments. 42 U.S.C. § 247d.
124. 21 U.S.C. § 802(54)(D); 42 U.S.C. § 247d.
125. 42 C.F.R. § 8.11(h) (2019).
126. Id.
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specific public health emergency expires or is revoked. However, it
could give the agencies time to study whether the ongoing flexibilities
strike the right balance between treatment and diversion.
CONCLUSION
In response to the COVID-19 public health emergency, federal
regulators reduced barriers to initiating buprenorphine treatment using telemedicine and providing patients with a take-home supply of
methadone. This Essay provides an independent assessment of DEA
and SAMHSA’s authority to extend the flexibilities after the COVID19 public health emergency ends. It finds that DEA and SAMHSA possess the legal authority to extend the flexibilities without legislative
changes from Congress.
DEA could issue joint regulations that clear the path for additional use of telemedicine. Alternatively, DEA could fulfill its legal obligation to implement a special registration program for telemedicine.
SAMHSA could use its statutory authority to issue a rule codifying the
take-home flexibilities for methadone after consulting with DEA. SAMHSA could instead release a new guidance document implementing
these changes. As another alternative, SAMHSA and DEA could use the
opioid-specific emergency declaration to offer a longer term, but not
permanent, option to extend these flexibilities, perhaps while they
work on longer-term solutions like regulations.
With the hope that the COVID-19 pandemic will be behind us in
2021, there is a risk that these flexibilities will also come to an end. As
explained in this Essay, the agencies have multiple, lawful pathways
to extend these flexibilities beyond the pandemic and in support of
patients. To the extent that the evidence supports a policy shift in this
direction, the agencies have all the legal authority they need to chart
a new course.

